Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepQuant-SHUNT vs HVPG in Liver Disease
NCT02523196Phase 3Completed
- Sponsor
- University of Colorado Denver
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial, sponsored by University of Colorado Denver. Primary endpoints: HepQuant SHUNT Test Elimination Rate at 90 minutes, HepQuant SHUNT Test Systemic Clearance at 90 minutes and 6 more. Started Mar 2016; status: completed.
Beyond the preview
Go deeper on NCT02523196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523196.